Characterizing the Effects of Family History of Alcoholism on Alcohol Analgesia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jeff Boissoneault, PhD
- Phone Number: 352-273-6147
- Email: jboissoneault@phhp.ufl.edu
Study Contact Backup
- Name: Michael Robinson, PhD
- Phone Number: 352-273-6153
- Email: merobin@phhp.ufl.edu
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Center for Pain Research and Behavioral Health at UF Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Consume at least 1 drink/month over the past 6 months
Exclusion Criteria:
- History of chronic pain
- Current use of opioids
- Current major depression
- History of any psychotic disorder
- Undercontrolled hypertension or diabetes
- History of neurologic disease
- History of serious medical illness
- History of drug or alcohol dependence, including nicotine, or a pattern of hazardous alcohol use
- Safety concerns related to MRI (for example, implants or pacing devices)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Family History Positive
People reporting at least one parent with a history of alcohol problems.
|
A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
A beverage that does not meaningfully increase breath alcohol concentration.
|
|
Experimental: Family History Negative
People who do not report having a parent with a history of alcohol problems.
|
A beverage containing dose of ethanol individually determined to raise a participant's breath alcohol concentration up to approximately 0.08 g/dL.
A beverage that does not meaningfully increase breath alcohol concentration.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Heat Pain Threshold
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Temperature of heat stimulus applied to the foot at which participant reports pain.
VAS (visual analogue scale) pain intensity and unpleasantness ratings anchored from "no pain at all"/"not at all unpleasant" to "most intense/unpleasant imaginable" will be collected.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Heat Pain Tolerance
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Temperature of heat stimulus applied to the foot at which participant no longer tolerates pain.
VAS (visual analogue scale) pain intensity and unpleasantness ratings anchored from "no pain at all"/"not at all unpleasant" to "most intense/unpleasant imaginable" will be collected.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Heat Pain Intensity Ratings
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Participant perception of pain at a temperature producing a pain rating of approximately 5 out of 10 at baseline.
VAS (visual analogue scale) pain intensity ratings ranging from 0-100 and anchored from "no pain at all" to "most intense imaginable" will be collected.
Higher values reflect ratings of more intense pain.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Perceived Pain Relief
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Rating of relief from pain associated with consumption of the study beverage.
This is a VAS (visual analogue scale) assessing perceived pain relief ranging from 0-100 and anchored from "No relief at all" to "Most profound relief imaginable".
Higher scores reflect greater perception of pain relief.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Dorsolateral Prefrontal Cortex Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Pain-related activation in the dorsolateral prefrontal cortex associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Hypothalamus Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours
|
Pain-related activation in the hypothalamus associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours
|
|
Medial Prefrontal Cortex Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Pain-related activation in the medial prefrontal cortex associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Nucleus Accumbens Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Pain-related activation in the nucleus accumbens associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Periaqueductal Gray Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Pain-related activation in the periaqueductal gray associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Anterior Cingulate Cortex Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Pain-related activation in the anterior cingulate cortex associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Amgydala Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Pain-related activation in the amygdala associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Hippocampus Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Pain-related activation in the hippocampus associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Insula Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Pain-related activation in the insula associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Postcentral Gyrus Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Pain-related activation in the postcentral gyrus associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
|
Thalamus Activation
Time Frame: Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Pain-related activation in the thalamus associated with application of painful heat vs. non-noxious warmth to the bottom of the right foot during fMRI acquisition.
Scores are beta-weights associated with fit of activity within the region to activity predicted by convolving the canonical hemodynamic response function with the heat pain stimulus paradigm assessed using general linear modeling.
Positive beta weights reflect activation associated with the stimulus paradigm, while negative beta weights reflect deactivation.
|
Day 1; Day 2 (Laboratory sessions will be separated by at least 48 hours.)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jeff Boissoneault, PhD, Assistant Professor
Publications and helpful links
General Publications
- Boissoneault J, Stennett B, Robinson ME. Acute alcohol intake alters resting state functional connectivity of nucleus accumbens with pain-related corticolimbic structures. Drug Alcohol Depend. 2020 Feb 1;207:107811. doi: 10.1016/j.drugalcdep.2019.107811. Epub 2019 Dec 24.
- Sevel L, Stennett B, Schneider V 2nd, Bush N, Nixon SJ, Robinson M, Boissoneault J. Acute Alcohol Intake Produces Widespread Decreases in Cortical Resting Signal Variability in Healthy Social Drinkers. Alcohol Clin Exp Res. 2020 Jul;44(7):1410-1419. doi: 10.1111/acer.14381. Epub 2020 Jun 18.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB201800992-N
- R01AA025337 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.